CClinicalTrials.gg
CompletedNCT05563090Updated May 4, 2025

Investigating the Syndrome Differentiation of Diabetic and Pre-diabetic Using Digitalized TCM Diagnostic Tools

An observational study in Diabete Mellitus, Pre-diabetes and Healthy, sponsored by Singapore Chung Hwa Medical Institution. Completed at 1 site in Singapore. Open to participants aged 21 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by Singapore Chung Hwa Medical Institution · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
171
Ages
21 Years to 75 Years
Sex
All
01

Study summary

The investigators aim to objectively identify the Traditional Chinese Medicine (TCM) syndrome differentiation of type II diabetic and prediabetic patients in Singapore through modern technologies thereby potentially increasing the accuracy of identification, diagnosis, and prevention of diabetes and prediabetes through a system of targeted treatment. This observational study integrates the concept of TCM diagnostic methods with modern tools aim to provide an objective view on the syndrome differentiation of diabetic and prediabetic patients in Singapore and hence provide a guideline in the treatment options targeted specifically at Singaporeans demographic.

A total of 250 subjects with 50 allocated in each group will be recruited to ensure a sufficient sample size for statistical analysis of the diabetic and prediabetic syndrome differentiation. Subjects aged 21-65 years old, of either gender, with no limitations on race, and is diagnosed with either diabetes (FPG ≥ 7.0 mmol/L, or 2hPG ≥ 11.1mmol) or prediabetes (IFG of FPG 6.1-6.9 mmol/L, and/or IGT with 2hPG of 7.8-11.0 mmol/L) will be included.

Subjective and objective assessments through health evaluation, Physical Activity Questionnaire and Sugar Intake, Constitution in Chinese Medicine Questionnaire, radial pulse diagnosis and tongue diagnosis will be performed for each subject in a single visit. Statistical analysis of assessments will be conducted using unpaired t-test with significance level of p\<0.05. Statistical software SPSS 15.0 (SPSS Inc.) will be used for the analysis.

Read the detailed description

Singapore's age-adjusted comparative prevalence of diabetes is at 5.5% in 2019 down from 10.2% in 2010, whereas the global average is at 8.3%. However, approximately 640,000 Singapore citizens 18 years and above are diagnosed with diabetes, and around 650,000 citizens are prediabetic.

The investigators aim to objectively identify the Traditional Chinese Medicine (TCM) syndrome differentiation of type II diabetic and prediabetic patients in Singapore through modern technologies thereby potentially increasing the accuracy of identification, diagnosis, and prevention of diabetes and prediabetes through a system of targeted treatment.

The investigators hypothesize that the TCM syndrome differentiation of 'xiao-ke' in Singapore is different from that of the ones defined in TCM Internal Medicine, which is based on China demographics.

This observational study integrates the concept of TCM diagnostic methods with modern tools aim to provide an objective view on the syndrome differentiation of diabetic and prediabetic patients in Singapore and hence provide a guideline in the treatment options targeted specifically at Singaporeans demographic.

The investigators will attempt to recruit a total of 250 subjects with 50 allocated in each group to ensure a sufficient sample size for statistical analysis of the diabetic and prediabetic syndrome differentiation. Subjects aged 21-75 years old, of either gender, with no limitations on race, and is diagnosed with either diabetes (FPG ≥ 7.0 mmol/L, or 2hPG ≥ 11.1mmol) or prediabetes (IFG of FPG 6.1-6.9 mmol/L, and/or IGT with 2hPG of 7.8-11.0 mmol/L) will be included.

Subjective and objective assessments through health evaluation, Physical Activity Questionnaire and Sugar Intake, Constitution in Chinese Medicine Questionnaire, radial pulse diagnosis and tongue diagnosis will be performed for each subject in a single visit. Statistical analysis of assessments will be conducted using unpaired t-test with significance level of p\<0.05. Statistical software SPSS 15.0 (SPSS Inc.) will be used for the analysis.

02

Conditions studied

  • Diabete Mellitus
  • Pre-diabetes
  • Healthy
  • Hypertension
  • Dyslipidemia Associated With Type II Diabetes Mellitus

Keywords

  • Diabetes Mellitus
  • Type II diabetes
  • Pre-diabetes
  • Healthy subjects
  • hypertension
  • dyslipidemia
  • TCM
  • TCM diagnosis
  • Pulse diagnosis
  • Tongue diagnosis
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 171 is below the median of 210 across 1,359 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Singapore Chung Hwa Medical Institution is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The subjects need to be at 21-75 years old, of either gender, with no limitations on race, and is clinically diagnosed by Western medical doctors with either diabetes (FPG of ≥ 7.0 mmol/L, 2hPG of ≥ 11.1mmol, or HbA1c of > 6.5%) or prediabetes (IFG of FPG 6.1-6.9 mmol/L, and/or IGT with 2hPG of 7.8-11.0 mmol/L). Healthy or sub-healthy subjects without any significant health related issues, eg. clinically diagnosed chronic conditions such as diabetes, hypertension or dyslipidemia, will be recruited as the control group. The health evaluation form (Annex 1) will be used to verify that these healthy subjects (1) do not have any family history of diabetes, and (2) do not have unusual high fasting blood glucose detected within one year.

Inclusion criteria

  • Aged 21-75 years old, inclusive;
  • Clinically diagnosed with one of the following:

    1. Type II Diabetes Mellitus with or without hypertension and dyslipidemia
    2. Prediabetes with or without hypertension and dyslipidemia
    3. Healthy or sub-healthy subject without clinically diagnosed chronic conditions such as diabetes, hypertension or dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • Subjects diagnosed with Gestational Diabetes
  • Subjects who are pregnant or lactating
  • Subjects with chronic heart failure, history of carcinomas with treatment of chemotherapy/radiotherapy, psychological, or psychiatric disorders
  • Subjects with heart diseases and transplanted devices such as pacemakers;
  • Subjects with acute infections such as upper respiratory infections, acute gastroenteritis, or urinary tract infections;
  • Subjects unable to undergo evaluation with the pulse sphygmograph, tongue detection or complete the questionnaire;
  • Subjects with communication disorders
  • Subjects with gastroenterology diseases or are diagnosed with 'spleen and stomach deficiency' (脾胃虚弱)
  • Subjects undergoing TCM treatment for diabetes or pre-diabetes within 1 week
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
171 participants (actual)
Patient registry
No

Groups and cohorts

  • 0HEA

    Healthy or sub-healthy subject without clinically diagnosed chronic conditions such as diabetes, hypertension or dyslipidemia

    Other: Questionnaires+Tongue diagnosis+Pulse diagnosis

  • 1PRE

    Prediabetes with IFG of FPG 6.1-6.9 mmol/L, and/or IGT with 2hPG of 7.8-11.0 mmol/L

    Other: Questionnaires+Tongue diagnosis+Pulse diagnosis

  • 2DIA

    Diabetes with FPG of ≥ 7.0 mmol/L, 2hPG of ≥ 11.1mmol, or HbA1c of \> 6.5%

    Other: Questionnaires+Tongue diagnosis+Pulse diagnosis

  • 3PREHD

    Prediabetes with hypertension and dyslipidemia

    Other: Questionnaires+Tongue diagnosis+Pulse diagnosis

  • 4DIAHD

    Diabetes with hypertension and dyslipidemia

    Other: Questionnaires+Tongue diagnosis+Pulse diagnosis

Interventions

  • OtherQuestionnaires+Tongue diagnosis+Pulse diagnosis

    Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools

06

What researchers measure

Primary outcomes

  1. The Constitution in Chinese Medicine Questionnaire (CCMQ)

    The CCMQ, published by the China Association of Chinese Medicine in 2009, will be adopted to assess the body constitution of each subjects based on TCM principles \[26\]. Refer to Annex 3. There are nine different types of body constitution, including (a) Normality; (b) Qi deficiency; (c) Yin deficiency; (d) Yang deficiency; (e) Phlegm-dampness; (f) Damp-heat; (g) Blood stasis; (h) Qi depressed; (i) Inherited special constitution. Each subject will answer seven to eight questions in each category. The scoring algorithm indicates the likelihood of a specific type of body constitution with a higher score.

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  2. Physical Activity Questionnaire and sugar intake

    Level of physical activity related to the last three months will be recorded through the Physical Activity Questionnaire. Sugar intake includes sweet or carbonated drinks, desserts like chocolates and cakes, 0 - 2, 3 - 6, or more than 7 times a week will also be recorded. Refer to Annex 2. This will help to identify the risk factors involved and identify the correlation between the body constitutions and various types of 'xiao-ke' based on TCM syndrome differentiation.

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  3. Pulse sphygmograph

    The Asia Plus Pen Pulse Analysis System Model PPAS-93 (Asia Plus Bio Tech Co., Ltd, Taiwan) would be used in the identification of RPPW of the subjects in this study. The Asia Plus Pen Pulse Analysis System Model PPAS-93 (Figure 11) is a noninvasive device that consist of a high precision pressure sensor pen and a pulse analyzer. The 3D pulse detector is a handheld pen that digitalizes the biological signal of RPPW and provides a graphical analysis. The electronic device contains a high precision pressure sensor, a filter, an amplifier, and a signal recording card connected to signal analysis software. The frequency response is 0.1-50 Hz, and the sampling rate is 3000 Hz.

    Time frame: One-time assessment within 30mins after undergoing the questionnaires

  4. Tongue imaging device

    China Artificial Intelligence Health Status Identification System Model Number YZKJ-SMZY-1AI (Figure 12) will be used in the imaging and analysis of the subject's tongue. The noninvasive device captures the image of the tongue through an inbuilt camera supported by LED lights within the device. A monitor that is connected to the imaging device would provide a live video feedback on the positioning of the tongue. The images of the subjects' face, tongue, and sublingual collaterals will then be compared and analyzed for the similarities against standard images of tongue analysis using an artificial intelligence system.

    Time frame: One-time assessment within 30mins after undergoing the questionnaires

Secondary outcomes

  1. Health Evaluation - Age

    Demographic information eg age in years will be collected.

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  2. Health Evaluation - Gender

    Demographic information eg gender will be collected.

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  3. Health Evaluation - Weight

    Weight in kilogram will be recorded

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  4. Health Evaluation - Height

    Height in meters will be recorded

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  5. Health Evaluation - BMI

    Weight in kilogram and height in meters will be aggregated to derive the BMI in kg/m\^2.

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  6. Health Evaluation - blood sugar level

    Blood glucose in fasting, 2hPG or HbA1c (in mmol/L) results if available in patient's regular blood test report

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  7. Health Evaluation - Vital signs

    Vital signs including systolic blood pressure, diastolic blood pressure in mmHg

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  8. Health Evaluation - Radial pulse rate

    Vital signs including radial pulse rate (bpm)

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  9. Health Evaluation - Medications

    Western and Chinese medications and nutritional supplements consumed by the subjects will be recorded to identify possible intervention and correlation towards TCM syndrome differentiation.

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

  10. Health Evaluation - Existing symptoms

    The existing symptoms of subjects will be recorded to identify the possible correlation towards TCM syndrome differentiation.

    Time frame: One-time assessment within 30mins before undergoing the tongue and pulse diagnosis.

07

Study locations

1 site
  • Singapore Chung Hwa Medical Institution
    Singapore, 319522, Singapore
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05563090
Lead sponsor
Singapore Chung Hwa Medical Institution
Collaborators
Ministry of Health, Singapore
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Sep 17, 2022
Primary completion
Apr 1, 2025
Completion
Apr 1, 2025
Last update
May 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion